바이오의약품 및 바이오 의료 시장 : 제품 유형(바이오의약품, 바이오 의료, 세포 및 유전자 치료, 바이오인포매틱스, 분자 효소 및 키트), 용도, 지역별 - 규모, 점유율, 전망, 기회 분석(2022-2030년)
Biopharmaceutical & Biomedicine Market, by Product Type (Biopharmaceutical, Nanomedicine, Cell & Gene Therapy, Bioinformatics, & Molecular Enzymes & Kits), by Application, & by Region - Size, Share, Outlook, & Opportunity Analysis, 2022 - 2030
상품코드 : 1098658
리서치사 : Coherent Market Insights
발행일 : 2022년 06월
페이지 정보 : 영문
US $ 4,500 ₩ 6,093,000
PDF (Single User License)
US $ 7,000 ₩ 9,478,000
PDF (Multi User License)
US $ 10,000 ₩ 13,540,000
PDF (Enterprise User License)


한글목차

바이오의약품 및 바이오 의료 시장은 치료법의 진화, 세포치료 및 재생의료 등의 급속한 기술 혁신에 의해 성장을 보일 것으로 예측됩니다. 부작용이 적고, 높은 유효성과 강력한 작용이 있으며, 질환을 치유하는 능력이 바이오의약품 및 바이오 의료의 큰 이점입니다.

세계의 바이오의약품 및 바이오 의료 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 법규제 환경, 기술 동향, 시장 규모의 추이·예측, 각종 부문·지역/주요 국가별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 조사 목적·전제조건

제2장 시장의 전망

제3장 시장 역학·규제·동향 분석

제4장 세계의 바이오의약품 및 바이오 의료 시장 : COVID-19의 영향

제5장 세계의 바이오의약품 및 바이오 의료 시장 : 제품 유형별

제6장 세계의 바이오의약품 및 바이오 의료 시장 : 용도별

제7장 세계의 바이오의약품 및 바이오 의료 시장 : 지역별

제8장 경쟁 구도

제9장 섹션

KSA 22.07.20
영문 목차

영문목차

A biopharmaceutical (biological or biologic), which consists of sugars, proteins, nucleic acids, living cells, or tissues, is a medicinal product semi-synthesized from biological sources such as humans, animals, or microorganisms. Biopharmaceuticals has emerged as one of the key segments with immense growth potential in the healthcare sector. Rising demand for effective treatment of diseases and rise in per capita healthcare expenditure has led to double digit revenue growth for market players in the recent past.

The biopharmaceutical and biomedicine market is expected to gain further traction, with evolving treatment options and rapid technological innovation such as cell therapy and regenerative medicines. Fewer side effects, high effectiveness and potent action, and ability to cure the disease rather than treating it are some of the major advantages of biopharmaceutical and biomedicine drugs. Currently, biopharmaceuticals accounts for over one-fifth of pharmaceutical market, and this percentage share of biopharmaceutical is expected to increase, owing to its advantages compared to totally synthesized pharmaceutical drugs.

Market Dynamics

Increasing adoption of inorganic strategies by key players in market such as acquisitions is expected to drive market growth over the forecast period. For instance, in May 2022, GSK plc, a multinational pharmaceutical company, announced that it had entered into a definitive agreement to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. The acquisition will further strengthen the vaccines research & development pipeline of GSK plc and broaden its existing scientific footprint in Boston, U.S.

Key features of the study:

Detailed Segmentation:

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Biopharmaceutical and Biomedicine Market- COVID-19 Impact Analysis

5. Global Biopharmaceutical and Biomedicine Market, By Product Type, 2017 - 2030, (US$ Million)

6. Global Biopharmaceutical and Biomedicine Market, By Application, 2017 - 2030, (US$ Million)

7. Global Biopharmaceutical and Biomedicine Market, By Region, 2017 - 2030, (US$ Million)

8. Competitive Landscape

9. Section

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기